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http://dx.doi.org/10.1016/j.ccr.2012.08.003SUMMARYTwist proteins have been shown to contribute to cancer development and progression by impinging on
different regulatory pathways, but their mechanism of action is poorly defined. By investigating the role of
Twist in sarcomas, we found that Twist1 acts as a mechanism alternative to TP53mutation and MDM2 over-
expression to inactivate p53 in mesenchymal tumors. We provide evidence that Twist1 binds p53 C terminus
through the Twist box. This interaction hinders key posttranslational modifications of p53 and facilitates
its MDM2-mediated degradation. Our study suggests the existence of a Twist box code of p53 inactivation
and provides the proof of principle that targeting the Twist box:p53 interactionmight offer additional avenues
for cancer treatment.INTRODUCTION
Twist1 and Twist2 (collectively hereafter referred as ‘‘Twist’’) are
closely relatedmembers of a family of bHLH transcription factors
involved in gastrulation and mesoderm specification. Typically,
Twist proteins regulate the expression of target genes by
binding, as homo- or heterodimers, to E-box-containing pro-
moters. Consistent with the role in tissue specification, the
expression of Twist1 in mouse embryo follows mesoderm
induction and becomes negligible in adult mesenchymal
tissues, except a population of quiescent mesodermal stem
cells. Twist2 is also involved in mesoderm development, but its
activation occurs later than Twist1 and is essentially restricted
to the dermis (Barnes and Firulli, 2009; Castanon and Baylies,
2002; Qin et al., 2012; Tukel et al., 2010).Significance
Although sarcomas are relatively rare tumors, their aggressive
make them one of the most challenging types of cancer. Int
response, a large fraction of sarcomas retain wild-type TP53, in
for p53 inactivation in these tumors. Here, we provide evidenc
important strategy of attenuation of the p53 response in sarc
that retain wild-type TP53. Moreover, we show that, by establis
of p53 and facilitates its degradation. Thus, targeting the Twis
treatment.
404 Cancer Cell 22, 404–415, September 11, 2012 ª2012 Elsevier InTwist proteins were first associated with cancer on the basis
of their ability to promote the bypass of cellular safeguard
programs. Both genes were isolated through a genetic screen
for cDNAs capable of overriding Myc-induced apoptosis, and
Twist1 was found to be overexpressed in rhabdomyosarcomas,
where it was suggested to support oncogenic transformation
and to inhibit myogenic differentiation (Maestro et al., 1999).
Subsequently, de novo Twist1 activation was reported in several
types of cancer including neuroblastomas (Valsesia-Wittmann
et al., 2004) and carcinomas, where it was shown to contribute
to metastatic progression through the induction of epithelial-
mesenchymal transition (EMT) (Karreth and Tuveson, 2004;
Yang et al., 2004). A role for Twist proteins in stemness has
also recently emerged (Cakouros et al., 2010; Vesuna et al.,
2009).behavior, resistance to therapies, and often early-age onset
riguingly, despite clear evidence of attenuation of the p53
dicating that mechanisms different frommutations account
e that Twist1-induced destabilization of p53 represents an
omas. We show that Twist1 accumulates mostly in tumors
hing direct interaction, Twist1 hinders key phosphorylations
t1:p53 interaction might offer additional avenues for cancer
c.
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A Twist box Code of p53 InactivationThe different consequences of constitutive Twist expression
suggest that these transcription factorsmay contribute to tumor-
igenesis and neoplastic progression through different routes. In
particular, Twist1 has been demonstrated to bind the E-cadherin
promoter to suppress its transcription, thus facilitating EMT and
metastatic spreading of epithelial tumors (Karreth and Tuveson,
2004; Yang et al., 2004). Twist proteins have also been shown to
suppress the transcription of p19ARF, thus attenuating onco-
gene-induced p53 response, and p16INK4a, thus allowing
cancer cells to escape Rb-mediated cell cycle control (Ansieau
et al., 2008; Feng et al., 2009; Kwok et al., 2007; Lee and
Bar-Sagi, 2010; Li et al., 2009; Maestro et al., 1999; Shiota
et al., 2008; Stasinopoulos et al., 2005; Valsesia-Wittmann
et al., 2004; Vichalkovski et al., 2010). Moreover, Twist mediates
mesenchymal stem cell self-renewal, and Twist1-induced EMT
requires BMI1, thus linking EMT and stemness (Isenmann
et al., 2009; Yang et al., 2010). Finally, it has been proposed
that EMT and bypass of safeguard programs might represent
two sides of the same coin (Ansieau et al., 2008). Overall, the
emerging picture is that Twist proteins play important roles in
cancer, but the fact that they intersect multiple different path-
ways makes it hard to dissect the mechanisms of action as
EMT/metastasis factors and as primary oncogenic drivers.
Sarcomas represent a heterogeneous group of mesenchymal
tumors that account for about 5% of adult and 10% of pediatric
neoplasias. Sarcomas include over 60 histopathological cate-
gories and are broadly classified into two cytogenetic groups,
complex and simple karyotype, and these latter are often char-
acterized by reciprocal translocations or targeted amplifications
(Borden et al., 2003; Fletcher et al., 2002; Helman and Meltzer,
2003). A large fraction of localized sarcomas, especially the
simple karyotype ones, retain wild-type TP53 but their p53
response is attenuated. Thus, other, still elusive, mechanisms
are likely responsible for p53 inactivation in these tumors.
We reasoned that, being mesenchymal in nature, sarcomas
offer the opportunity to discern the functions of Twist related to
the induction of EMT, typically occurring in carcinomas, from
those more specifically related to the interference with tumor-
suppressive pathways. Thus, in the attempt to provide a better
understanding on how Twist contribute to tumorigenesis, we
sought to investigate the role of Twist in antagonizing p53,
focusing on sarcomas as a tumor model.
RESULTS
Twist1 Is Overexpressed and Undergoes Copy-Number
Gain in Sarcomas
To assess the oncogenic role of Twist in the context of mesen-
chymal tumors, 146 sarcomas and adjacent normal tissues
were investigated by immunohistochemistry (IHC). With the
exception of dermal fibroblasts, where scattered nuclear reac-
tivity was observed, normal adult mesenchymal tissues were
essentially negative for Twist1. In contrast, a strong and diffuse
nuclear accumulation of Twist1 was observed in over 60% of
soft-tissue sarcomas of different subtypes (Figure 1A; see
Table S1 available online). Overexpression of Twist2 was
uncommon in sarcomas (6/84 cases) and sarcoma cell lines
(Figure S1A). Fluorescence in situ hybridization (FISH) analyses
with a probe encompassing the TWIST1 locus revealed that, inCan9 of 19 (47%) Twist1 IHC+ frozen samples, Twist1 accumulation
was associated with TWIST1 copy-number gain (Figure 1B;
Table S2).
In light of the role of Twist1 in EMT, we then compared Twist1
expression pattern in sarcomas and carcinomas. In contrast to
the widespread and robust accumulation detected in sarcomas,
a weak-moderate nuclear expression of Twist1 was observed in
10%–30% of breast, colorectal, prostate, and lung carcinomas,
often confined to the invasion front (Figure 1A; Table S3).
Twist1 Overexpression Serves as an Alternative
Mechanism of p53 Inactivation during Sarcomagenesis
Because mutations of TP53 are rare in sarcomas and Twist1 has
been suggested to attenuate the p53 pathway (Ansieau et al.,
2008; Feng et al., 2009; Kwok et al., 2007; Lee and Bar-Sagi,
2010; Li et al., 2009; Maestro et al., 1999; Shiota et al., 2008;
Stasinopoulos et al., 2005; Valsesia-Wittmann et al., 2004;
Vichalkovski et al., 2010), we asked whether the overexpression
of Twist1 could account for p53 inactivation in sarcomas retain-
ing wild-type TP53. We first focused on leiomyosarcomas (LMS),
a sarcoma subtype that has one of the highest frequencies of
TP53 mutations (Dei Tos et al., 1996; Hall et al., 1997). In partic-
ular, we analyzed localized/nonmetastatic tumors because
sarcomas may acquire p53 mutations that contribute to tumor
aggressiveness during progression (Cordon-Cardo et al.,
1994). Among the 35 LMS analyzed, overexpression (>25%
positive cells) of p53, Twist1, Twist2, and MDM2 were found in
14, 15, three, and four cases, respectively (Table S4). TP53
missense mutations were found in eight cases (Figure 1C), all
displaying strong nuclear accumulation of p53; no mutation
was detected in samples that were negative or with focal/patchy
p53 immunostaining. Fourteen of 15 Twist1+ cases retained
wild-type TP53, the only exception being a case that was also
positive for MDM2. Thus, although not reaching the conventional
5% level of statistical significance, probably in part because of
the small sample size of these clinically rare tumors, the clus-
tering of Twist1-positivity among p53 wild-type LMS suggests
that overexpression of Twist1 may serve as a mechanism
alternative to TP53 mutations to inactivate the p53 response in
these tumors. To corroborate the role of Twist1 in inhibiting
p53, we then focused on liposarcomas (LS), which include
well-differentiated (WD) and dedifferentiated (DD) LS, and
myxoid/round cell (myxoid) LS. These LS display a simple karyo-
type and often retain the wild-type TP53. WD and the more
aggressive DD LS, which are considered the same entity at
different malignant stages, typically carry the amplification of
the chromosome region harboring the MDM2 locus (Fletcher
et al., 2002), and their p53 is inactivated as a result of enhanced
MDM2-mediated degradation. In contrast, the mechanism of
inactivation of p53 in myxoid LS, which are negative for
MDM2, remains unclear (Coindre et al., 2010; Mentzel and
Fletcher, 1995). In a series of 24 LS, all molecularly confirmed
to be TP53 wild-type, we observed an inverse correlation
between Twist1 andMDM2 overexpression: Twist1 was robustly
overexpressed in 13 of 14 MDM2 myxoid LS, whereas only
2 of 10 MDM2+ WD and DD LS expressed Twist1 (p = 0.00049)
(Figures 1A and 1C). Thus, Twist1 and MDM2 appear to be
essentially mutually exclusive in LS, supporting the notion that
Twist1 may inactivate p53 in mesenchymal tumors.cer Cell 22, 404–415, September 11, 2012 ª2012 Elsevier Inc. 405
Figure 1. Twist1 Is Overexpressed in Human Sarcomas and Supports the Oncogenic Transformation of Primary Mesenchymal Cells
(A) Immunostaining for Twist1 in sarcomas and in carcinomas. Scale bar: 100 mm.
(B) FISH analysis of TWIST1 in sarcomas overexpressing Twist1. TWIST1 probe (RP11-960P19) is in red; chromosome 7 centromeric probe (Alpha-Satellite 7) in
green. An example of copy-number gain involving the whole chromosome 7 (left panel) and of selective amplification of the TWIST1 locus (right panel) are shown.
Scale bar: 10 mm.
(C) Expression of Twist1 in LMS according to TP53 mutation status (upper) and in LS according to MDM2 expression (lower). The p value was calculated
according to the Fisher’s exact test.
(D) Twist1 and Twist2 induce tumorigenic conversion of RE-BJ cells. The table indicates the number of tumors generated by each oncogenic combination in a set
of injections. MDM2, a dominant-negative TP53 allele (dnp53, R175H), and a shRNA targeting p53 (shp53) were used as positive controls. Representative images
of RE-vector and RE-Twist1 xenografts are shown in the middle panel. Tumor size was measured weekly. The right panel shows the kinetics (average volume of
tumors, ± SD) of representative tumors.
See also Figure S1 and Tables S1, S2, S3, and S4.
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A Twist box Code of p53 InactivationTo functionally validate the role of Twist1 as an antagonist of
p53 during sarcomagenesis, we then probed its ability to
complement the transformation of human primary fibroblasts.
We showed previously that BJ human fibroblasts upon ex-
pression of HRasV12 and E1A (RE-BJ) gain a transformed
phenotype in culture but display negligible tumorigenic acti-
vity in xenograft assays. RE-BJ cells become tumorigenic406 Cancer Cell 22, 404–415, September 11, 2012 ª2012 Elsevier Infollowing inactivation of the p53 pathway (Di Micco et al.,
2006; Seger et al., 2002). We found that Twist-transduced
RE-BJ also generated tumors when injected into immunocom-
promised mice, supporting that Twist proteins may actually
sustain oncogene-induced transformation of cells of mesen-
chymal origin at least in part by antagonizing p53 (Figures
1D, S1C, and S1D).c.
Figure 2. Modulation of Twist1 Expression Affects p53 Response and Tumorigenicity in Sarcoma Cells
(A) Immunoblot of cells silenced for endogenous Twist1 expression by either shRNA (left) or siRNA (right). As a control (Ctr), shLuc and nontargeting siRNA pool
were used, respectively. Protein levels were normalized to GAPDH.
(B) Immunoblot of cells ectopically expressing either Twist1 (Tw) or GFP, as a control (Ctr). Cells were exposed to MG132 (10 mM) or vehicle (DMSO) for 4 hr, then
harvested.
(C) Cycloheximide-chase assays (CHX, 100 mg/ml) in Twist1-silenced HT-1080 and in VA-ES-BJ engineered to express ectopic Twist1. shGFP (shCtr) and GFP
(Ctr) were used as controls, respectively.
(D) Immunoblot of p53/ and p53/;Mdm2/MEF cotransfected with ectopic p53 (5 mg) and either myc-Twist1 (Tw) or empty control vector (Ctr) (15 mg). GFP
(1 mg) was used as a control of transfection. p53 expression levels (ect. p53) were corrected for transfection efficiency (p53/GFP ratio). This result was confirmed
on three independent experiments.
(E) BrdU incorporation assay in Twist1-silenced HT-1080 and Sal-1 cells. Histograms represent the mean plus SD.
(F) Xenograft growth of Twist1-silenced HT-1080 cells. Curves represent the average tumor volumes ± SD.
(G and H) HT-1080 cells were engineered to express combination of two shRNAs in pRS-Hyg and -Neo, as indicated. Controls (Ctr) were shGFP and shLuc. Cells
were seeded overnight and then were shifted to serum-free medium. Cell viability (G) and caspase 3/7 activation (H) were assessed 48 hr after starvation.
Histograms represent mean values plus SD.
(I) HT-1080 cells engineered and serum starved as in (G) and (H) were immunoblotted for the indicated proteins.
See also Figure S2.
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A Twist box Code of p53 InactivationTwist1 Enhances MDM2-Mediated Degradation of p53
We then assessed the effect of modulation of Twist expression in
a series of human sarcoma cell lines expressing wild-type p53
(Figures S1A and S1B). Downregulation of the endogenous
Twist1 by either stable expression of Twist1-specific shRNAs
(Ansieau et al., 2008; Yang et al., 2004) or transient transfection
of siRNAs stabilized p53 (Figure 2A). Conversely, ectopic Twist1
expression in Twist1 sarcoma cells reduced the p53 protein
level, without affecting p53 transcription (data not shown). ThisCandownregulation was reversed by proteasome inhibition, sug-
gesting that Twist1 promotes p53 proteasomal degradation
(Figure 2B). Accordingly, cycloheximide (CHX)-chase assays
indicated that the p53 half-life was increased from 1 hr to
3 hr in Twist1-silenced HT-1080 cells, whereas it was reduced
from45min to20min in VA-ES-BJ expressing ectopic Twist1
(Figure 2C). Moreover, cotransfection of Twist1 together with
p53 resulted in a slight but consistent reduction in p53 levels
(30%) in MDM2-proficient (p53/) but not in MDM2-deficientcer Cell 22, 404–415, September 11, 2012 ª2012 Elsevier Inc. 407
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A Twist box Code of p53 Inactivation(p53/; Mdm2/) mouse embryo fibroblasts (MEF) null for
endogenous p53 (Figure 2D), supporting a role for MDM2 in
Twist1-induced downregulation of p53.
Silencing of Twist1 Activates a p53 Response
in Sarcoma Cells
Under standard culture conditions, Twist1-depleted cells ex-
hibited impaired cell growth compared to control cells, as re-
vealed by longer doubling time (1.3 and 1.9 times longer for
HT-1080 and Sal-1, respectively; data not shown), decreased
BrdU incorporation (Figure 2E), and reduced S-phase fraction
(Figure S2A). Moreover, Twist1 knockdown was associated
with induction of acidic b-galactosidase activity (SA-b-gal) (Fig-
ures S2B and S2C), suggesting spontaneous premature senes-
cence, and with reduced tumorigenicity in xenograft models
(Figures 2F and S2D). Twist1 depletion correlated also with en-
hanced sensitivity to serum starvation and UV radiation (Figures
2G, 2H, and S2C). This was paralleled by induction of p53 target
genes (Figure 2I) and was rescued by silencing of p53 (Figures
2G–2I and S2E). No relevant perturbation in cell growth was
observed following Twist1 silencing in sarcoma cells that were
either homozygously deleted (SAOS-2) or mutated (SK-UT-1)
for TP53 or that overexpressed MDM2 (SJSA) (Figure S2A).
Twist1 antagonizes oncogene-induced apoptosis at least in
part by interfering with the ARF/p53 pathway. However, a signif-
icant fraction of sarcomas and sarcoma-derived cell lines
(including HT-1080, Sal-1, MES-SA, VA-ES-BJ, and WE68) are
deficient for INK4a/ARF, and Twist1 can attenuate Myc-induced
apoptosis in p53 wild-type/ARF null U2-OS cells (Figure S2F).
This suggests that Twist1 impinges on p53 also independently
of ARF.
Twist1-Mediated Antagonism of p53 Activity Does Not
Require an Intact Basic Domain or Binding to p300/CBP
To shed light on the mechanisms of Twist-induced destabili-
zation of p53, we characterized Twist1 domains required to
antagonize the p53 response. Twist1 is known to regulate the
transcription of several genes by binding their promoters through
its basic DNA binding domain (Cakouros et al., 2010; Yang et al.,
2010). We therefore investigated whether Twist1 modulated
p53 response through a direct transcriptional mechanism. To
this end, a series of Twist1 mutants defective for DNA binding
(Spicer et al., 1996) (Figure 3A) were assayed for inhibition of
p53-mediated transcription and apoptosis in E1A/Ras MEF
(ER-MEF), which represent a well-defined setting of oncogene-
induced/p53-dependent apoptosis (Lowe et al., 1993). In
these cells, ectopic Twist expression attenuates p53-induced
apoptosis (Maestro et al., 1999), whereas silencing of endoge-
nous Twist1 results in enhanced stress sensitivity (Figures
S3A–S3E). Despite loss of DNA binding activity, Twist1 basic
domain mutants retained ability to protect ER-MEF from p53-
mediated apoptosis (Figures 3B and S3F) and to repress
a p53-responsive promoter (Figure S3G). More importantly,
similar to full-length Twist1, the mutant carrying a deletion of
the whole basic domain (Db) was capable of converting nontu-
morigenic RE-BJ into tumorigenic cells (Figures 3C and S3H).
Taken together, these data indicated that Twist1 could antago-
nize p53 and contribute to cancer development through an
E-box-independent mechanism.408 Cancer Cell 22, 404–415, September 11, 2012 ª2012 Elsevier InTwist1 has been hypothesized to interfere with p300/CBP-
mediated activation of p53 (Ansieau et al., 2008; Hamamori
et al., 1999; Shiota et al., 2008). To test this hypothesis, we
generated a Twist1 mutant devoid of the major p300/CBP
binding region (D30-60) (Figure 3A). The p300/CBP binding
region overlaps Twist1 nuclear localization signal (NLS), and,
therefore, theD30-60mutant lost nuclear localization (Figure 3D).
To circumvent this problem, an ectopic NLS (KRKK)was inserted
at the N terminus (D30-60NLS). Despite impaired p300 binding,
Twist1 D30-60NLS retained the power of repressing p53-
mediated transcription (Figures S3G–S3I) and promoting cell
survival (Figure 3D). This result demonstrates that the binding
to p300/CBP is dispensable for Twist1-mediated inhibition of
p53. Moreover, the fact that only the mutant expressed in
the nucleus was capable of preventing p53-dependent
apoptosis indicates that Twist1 requires nuclear localization to
antagonize p53.
Twist and p53 Establish Tail-Tail Interaction
that Involves the Twist box and p53 C-Terminal
Regulatory Domain
It has been recently proposed that p53 may interact with the N
terminus of Twist1 (Shiota et al., 2008). We then hypothesized
that Twist1 could inhibit p53 response in sarcomas by directly
targeting p53. Immunoprecipitation of endogenous Twist1 re-
sulted in coprecipitation of endogenous p53 (Figure 4A), indi-
cating that Twist1 does interact with p53 in sarcoma cells. The
interaction is direct, as demonstrated by GST pull-down and
coprecipitation assays using GST-Twist1 and His-p53 recombi-
nant proteins (Figure 4B).
GST pull-down experiments confirmed the suggested weak
interaction between p53 and the very N terminus of Twist1 (Fig-
ure S4A). However, we have shown that the deletion of this
region does not affect the ability of Twist1 to antagonize p53-
dependent transcription and apoptosis (D30-60NSL) (Figures
3D and S3G), ruling out a major biological relevance for this
particular interaction. Instead, we found that p53 binds robustly
to the C terminus of Twist1. In fact, both in vitro and in vivo
(Figures S4A and S4B) coprecipitation experiments indicated
that Twist1 engages a 20-aa stretch, corresponding to the highly
conserved C-terminal region named Twist box (Bialek et al.,
2004), to interact with p53 (Figure 4C).
The specificity of the bindingwas confirmed byGST pull-down
using a Twist box peptide displayed from the active site loop of
thioredoxin (T175-199), implying that this minimal region is
both required and sufficient for p53 interaction. More impor-
tantly, Twist box-defective mutants were impaired in their
ability to antagonize p53-depedent apoptosis (Figure 4D) and
transcription (Figure S3G). This corroborates the relevance of
the Twist box in the inhibition of p53. Intriguingly, this domain
is conserved also in Twist2 and, in fact, Twist2 protected
ER-MEF and bound p53 as efficiently as Twist1 (Figure 4D;
Figure S4C).
Reciprocal mapping experiments revealed that p53 interacts
with Twist through its C-terminal regulatory domain (aa 354–
393) (p53CTD) (Figures 4E and S4D). These results were also
corroborated by in silico prediction of protein:protein interaction.
Docking simulation of human Twist1 and p53 models provided
the best docking score for p53CTD and Twist1 Twist box, withc.
Figure 3. Twist1 Inhibits p53 also Independently of E-Box and p300/CBP Binding
(A) A schematic representation of the mouse Twist1 and various mutants. A114P and A117P carry a destabilizing proline into the basic domain (b); Db is a whole
basic-domain deletion mutant; NLS indicates Twist1 nuclear localization signal, bHLH the basic Helix-Loop-Helix domain; and eNLS denotes the ectopic nuclear
localization signal.
(B) Cell viability of ER-MEF engineered as indicated after oncogene-mediated/p53-dependent apoptosis (0.1 mg/ml doxorubicin, 24 and 48 hr). Histograms
indicate the mean percentage of treated/untreated cells, plus SD. Ctrl are control vector-infected cells.
(C) Representative tumor explants from RE-BJ cells engineered to expressMDM2, Twist1, orDb Twist1 (left). The number of tumors generated in a representative
set of injections is reported on the right. Pictures were taken at week 5.
(D) Left: Immunofluorescence of ER-MEF engineered to express the indicated Twist1 myc-tag constructs. Nuclei are stained with DAPI. Scale bar: 50 mm. Right:
Cell viability of ER-MEF engineered as indicated after apoptotic challenge (0.1 mg/ml doxorubicin, 24 and 48 hr). Histograms indicate the mean percentage of
treated/untreated cells, plus SD.
See also Figure S3.
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A Twist box Code of p53 Inactivationa predicted interface of the complex of 980 A˚2 and a highly
significant lowest energy cluster population (187/500 individ-
uals) (Figures 5A and 5B). In agreement with GST pull-down
data, docking simulations ruled out a major role for other regions
of p53 in the interaction with Twist1, including the p53 ‘‘core
domain’’ (Cho et al., 1994) (lowest energy cluster: 55/500 indi-
viduals). The relevance of Twist box in Twist:p53 interaction
was corroborated by the finding that single amino acid substitu-
tions in the Twist box affected the binding in vitro to p53
(Figure 5C).
Twist1 Hinders p53 Phosphorylation at Ser392
Posttranslational modifications of C-terminal residues are
involved in the regulation of p53 activity and stability (Xu,
2003). Intriguingly, in silico docking experiments indicated that
one of the p53 residues involved in the interaction with Twist1
is the highly conserved Ser392 (Ser389 in mouse). In fact, in
the Twist1:p53 complex, Ser392 is directly engaged in hydrogen
bonds with Arg191 and Ala200 of Twist1 and is shielded by the
Twist1 C terminus (Val189-His202) (Figures 5B and 5D).CanPhosphorylation of Ser392 has been implicated in the regu-
lation of p53 stability and activity (Cox and Meek, 2010; Hupp
et al., 1992; Kapoor et al., 2000; Sakaguchi et al., 1997; Yap
et al., 2004). Moreover, mice expressing a p53 mutant that
cannot be phosphorylated at Ser389 (S389A) show impaired
p53 response, with increased sensitivity to chemical and UV-
induced carcinogenesis (Bruins et al., 2004; Hoogervorst et al.,
2005).
We then hypothesized that Twist1 may affect p53 by directly
inhibiting Ser392 phosphorylation. Indeed, we found that
silencing of Twist1 was associated with a significant increase
in the fraction of p53 phosphorylated at Ser392 (PSer392).
Conversely, PSer392 was diminished in the cells engineered
to express Twist1 or p53 binding-proficient Twist1 mutants
but was unaffected in the cells expressing Twist box-deleted
mutants (Figures 6A and S5A). Moreover, transient cotransfec-
tion experiments indicated that, under conditions where
ectopic Twist1 efficiently promoted degradation and repressed
transcriptional activity of wild-type p53, Twist1-mediated inhibi-
tion was impaired toward Ser392 mutants of p53 (Figures 6Bcer Cell 22, 404–415, September 11, 2012 ª2012 Elsevier Inc. 409
Figure 4. Twist1 and p53 Bind Directly through the C Termini
(A) Cells lysates from HT-1080, SK-UT-1, and ER-MEF were incubated with either Twist1 monoclonal antibody (Twist1) or nonimmune IgG (Mock), immuno-
precipitated, and then blotted for coprecipitated p53 using anti-p53 antibodies. Twist1-negative MCF7 cells were used as a negative control. Input represents
10% of the whole cell lysate prior immunoprecipitation.
(B) Left panel: 35S-labeled in vitro translated p53 (IVT-p53) was incubated with equivalent amounts of GST-Twist1 or GST, used as a negative control. Complexes
were visualized by autoradiography. Right panel: recombinant His-p53 was incubated with equal amounts of glutathione agarose-bound GST or GST-Twist1.
After SDS-PAGE, complexes were detected with anti-GST and anti-His antibodies.
(C) A schematic representation of the mouse Twist and various Twist1 mutants (left) and summary of their ability to interact with p53 based on GST pull-down
experiments (right).
(D) Cell viability of ER-MEF engineered as indicated after apoptotic challenge (0.1 mg/ml doxorubicin, 24 hr and 48 hr). Histograms indicate the mean percentage
viability plus SD.
(E) A schematic representation of human p53 and derivative mutants (left) and summary of their ability to interact with Twist1 based on GST pull-down exper-
iments (right).
See also Figure S4.
Cancer Cell
A Twist box Code of p53 Inactivationand S5B). Finally, although it is still unclear what kinase phos-
phorylates Ser392 in vivo, casein kinase 2 (CK2) has been
shown to target Ser392 in vitro (Cox and Meek, 2010), and
we found that in vitro CK2-mediated phosphorylation at
Ser392 was attenuated in the presence of recombinant Twist1
(Figure S5C).
Twist1 failed to significantly affect the acetylation of Lys373
and Lys382 of p53, two residues involved in p53 stabilization
and included in the region of p53 engaged in the interaction
with Twist1 (Figures S5D–S5F). Although we cannot rule out
that Twist1 may alter other posttranscriptional modifications410 Cancer Cell 22, 404–415, September 11, 2012 ª2012 Elsevier Inrelevant for p53 activity and stability, our data indicate that
Twist1 attenuates the p53 response at least in part by impinging
on Ser392 phosphorylation. Intriguingly, different from Lys373
and Lys382 acetylation, Ser392 phosphorylation is triggered in
response to oncogene activation, both in human (Figures S5D–
S5F) and mouse fibroblasts (Figure S5G), and this correlates
with p53 induction. In the same cells, oncogene-induced trans-
formation was associated also with increased Twist1 levels
(Figures S5G and S5H). This suggests that the activation of
Twist1 may represent a mechanism elicited by oncogene-chal-
lenged cells to quench p53 response during transformation.c.
Figure 5. The Twist box Is Necessary for the Interaction with p53
(A) Ribbon representation of the interaction between p53 (red) and Twist1 (blue). The arrow indicates the Twist box:p53 interface.
(B) A summary of the residues of human Twist1 and human p53 involved in their binding, the functional groups of these residues involved in the interaction, and the
distance (in A˚) between the corresponding interacting functional groups as assessed by docking simulation. In mouse Twist1, the region involved in the binding
spans Ile138-His206.
(C) GST or GST-p53 pull-downs of IVT-Twist box or IVT-Twist box carrying the indicated amino acid substitutions.
(D) Magnification of the ribbon representation of Twist box (blue):p53 CTD (red) interaction. The hydrogen bond formed between p53 Ser392 and Twist1 Arg191
and the distance between these two residues in A˚ are indicated in yellow.
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A Twist box Code of p53 InactivationTwist1 Facilitates p53 Degradation by Increasing
the Affinity of p53 for MDM2
Modifications of p53CTD are known to modulate its suscepti-
bility to MDM2-mediated degradation. We therefore sought to
investigate the role of Ser392 in p53 degradation. CHX-chase
experiments in SAOS-2 and p53/ HCT116 cells engineered
to stably express p53 mutants at codon 392 indicated that
p53-S392E, a mutant mimicking constitutive phosphorylation
at Ser392, displayed a longer half-life than did the p53-S392A
phosphorylation-deficient mutant (Figure 6C). On a side note,
we noticed that both Ser392 mutants were more tolerated
compared to p53 WT, suggesting that Ser392 status affects
both p53 turnover and tumor-suppressive activity. Moreover,
the differential stability of Ser392 mutants was easier to appre-Canciate if the constructs were expressed following stable retroviral
infection instead of acute transfection, likely because of trans-
fection-induced stress response.
Intriguingly, the amount of MDM2 coimmunoprecipitated with
p53-S392E was significantly reduced (50%) compared to the
amount bound to the wild-type p53 and p53-S392A (Figure 6D).
This suggests that phosphorylation of Ser392 makes p53 less
prone to binding toMDM2, and hence toMDM2-driven degrada-
tion. In this scenario, by preventing Ser392 phosphorylation,
Twist1 might affect p53:MDM2 association. In agreement with
this hypothesis, we found that the increase in the overall levels
of p53 detected in HT-1080 cells following Twist1 knockdown
correlated with a slight but consistent decrease (30%) in the
amount of p53 complexed to MDM2 (Figures 6E and S5I).cer Cell 22, 404–415, September 11, 2012 ª2012 Elsevier Inc. 411
Figure 6. Twist1 Hinders Phosphorylation of p53 at Ser392 and Affects p53:MDM2 Interaction
(A) Immunoblot for p53 phosphorylated at Ser392 (P Ser392) of sarcoma cells silenced for Twist1 expression (left) or engineered to express ectopic Twist1 or
Twist1 mutants (right). Because modulation of Twist1 expression affects p53 expression levels, to better appreciate the effect of Twist1 on Ser392 phosphor-
ylation, samples were unevenly loaded to tentatively equalize the signals for total p53.
(B) Immunoblot of Twist1-negative p53/ HCT116 transfected with wild-type p53 or p53 mutants (4 mg) as indicated together with either myc-Twist1 (Tw) or
empty control vector (Ctr) (20 mg). GFP (1 mg) was included for normalization of transfection efficiency. This result was confirmed on three independent
experiments.
(C) Cycloheximide-chase assays (CHX, 250 mg/ml) in SAOS-2 cells infected with retroviral vectors encoding p53WT, p53 S392E (phospho-mimic), or p53 S392A
(phospho-impaired).
(D) SAOS-2 engineered to express p53 WT, S392A, or S392E p53 were treated with MG132 (10 mM, 8 hr), then were immunoprecipitated for p53. Immunoblots
were probed with anti-MDM2 and -p53 antibodies, and the amount of MDM2 coprecipitated was calculated asMDM2/p53 ratio. This result was confirmed in two
independent experiments.
(E) Twist1-silenced (shTw) and control (shCtr) HT-1080 were treated with MG132 (10 mM, 8 hr), immunoprecipitated for endogenous p53, and then probed for
MDM2 and p53. The amount of MDM2 bound to p53 was calculated as MDM2/p53 ratio. This experiment was done three times with two different p53 antibodies
(DO-1 and CM5).
(F) Immunoblot of p53/ HCT116 engineered to express either S392A or S392E p53, under standard conditions (NT), UV radiation (20 J/m2) or serum starvation
(30 hr).
(G) Immunoblots for p53 phosphorylation at Ser15 and Ser392 in sarcoma cells after modulation of Twist1 expression. GAPDH was used for normalization.
(H) Schematic representation of the proposed mechanisms of Twist1 contribution to oncogene-induced transformation and attenuation of p53 response.
See also Figure S5.
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A Twist box Code of p53 InactivationThus, Twist1 seems to promote p53 degradation by maintaining
p53 in an MDM2-accessible state.
It has been recently shown that, besides the canonical
N-terminal region (Kussie et al., 1996; Lin et al., 1994), p53 binds
MDM2 also with the CTD, and this interaction is hampered by
p53CTD modifications (Poyurovsky et al., 2010). Thus, Twist1
could interfere with this alternative mechanism of MDM2-
mediated degradation of p53. However, an interplay between
Ser392 and Ser15 of p53 has been proposed (Kapoor et al.,412 Cancer Cell 22, 404–415, September 11, 2012 ª2012 Elsevier In2000), and phosphorylation at Ser15 is well known to inhibit
MDM2 from binding N terminus p53 (Shieh et al., 1997). There-
fore, we investigated a possible cross-talk between these two
serines. We found that p53-S392E displayed a greater extent
of phosphorylation at Ser15 than did p53-S392A (Figure 6F).
Instead, constitutive phosphorylation at Ser15 (S15E) failed to
affect the extent of phosphorylation at Ser392 (Figure S5J).
This suggests a directional control of Ser15 phosphorylation by
Ser392 status. Moreover, modulation of Twist1 expression inc.
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A Twist box Code of p53 Inactivationsarcoma cells correlated with concordant variations in Ser392
and Ser15 phosphorylation (Figure 6G). Thus, besides interfering
with the p53CTD:MDM2 interaction, Twist1 might indirectly
affect also the canonical route of MDM2-mediated p53 degrada-
tion, suggesting the existence of multiple levels of controls of
Twist1 over p53 (Figure 6H).
DISCUSSION
By investigating the role of Twist1 in the context of sarcomas,
this study highlights an alternative mechanism of p53 inacti-
vation and provides evidence that Twist1 promotes MDM2-
mediated degradation of p53 by directly interacting with
its C-terminal regulatory domain and by interfering with key
phosphorylations.
We found that although Twist1 expression pattern in carci-
nomas is compatible with its proposed role inmalignant progres-
sion, the diffuse and strong Twist1 accumulation observed in
sarcomas suggests that Twist1 activation is an intrinsic com-
ponent of the transformed phenotype of tumor cells of mesen-
chymal origin. This hypothesis is supported by the finding that,
in these tumors, Twist1 accumulation often associates with
TWIST1 copy-number gain, a result that is in line with recent
evidence that one of the most frequent copy-number variations
in sarcomas involves the TWIST1 locus (Menghi-Sartorio et al.,
2001; Taylor et al., 2008).
In addition, we found that, in LS, Twist1 overexpression is
mutually exclusive with MDM2 positivity. In LMS, Twist1 accu-
mulation clustered among p53 wild-type tumors, although the
correlation was not statistically significant. This may be in part
due to the small sample size of these clinically rare tumors. On
the other hand, although early studies suggested that TP53
mutation and MDM2 overexpression were mutually exclusive,
subsequent studies have demonstrated that this is not a general
rule. Indeed, overexpression/amplification of MDM2 and TP53
mutation can coexist in the same tumor, likely because both
p53 and MDM2 are provided with functions independent of
each other (Cordon-Cardo et al., 1994; Ito et al., 2011; Manfredi,
2010). Similarly, Twist1 is also provided with p53-independent
functions that may play a role in sarcomagenesis (e.g., inhibition
of differentiation) and might account for Twist1 and MDM2
coexpression observed in six LMS retaining wild-type TP53.
Most evidence linking Twist1 to cancer refers to the ability of
Twist proteins to modulate the expression of target genes,
including ARF, thus affecting p53. This study provides evidence
that Twist1 affects p53 also through an E-box-independent
mechanism. In fact, we found that Twist1 mutants defective for
DNA binding retain the ability to interfere with the p53 response.
This indicates that Twist1 may participate to tumorigenesis and
promote the bypass of p53 failsafe programs apparently
through molecular mechanisms different from those that facili-
tate EMT in carcinomas.
Intriguingly, we found that Twist1 establishes a direct interac-
tion with p53 through the Twist box and that this interaction is
critical for Twist1 inhibition of p53. The Twist box corresponds
to a highly conserved 20-aa stretch at the C terminus of the
protein. Through the Twist box, Twist binds to and inhibits
RunX2 (Bialek et al., 2004), MEF2 (Spicer et al., 1996), ATF4
(Danciu et al., 2012), and RelA (Sosic et al., 2003). This suggestsCanthat the binding via Twist box is a leitmotif in the inhibition exerted
by Twist on other transcription factors. Here, we demonstrate
that Twist employs the Twist box to interact with the CTD
regulatory domain of p53. By binding p53CTD, Twist1 hinders
Ser392 phosphorylation, and this correlates with increased p53
sensitivity to degradation. Although Twist1 failed to significantly
affect Lys373 and Lys382 acetylation, we cannot exclude that,
by interacting with p53CTD, Twist1 may influence other modifi-
cations that affect p53 functions. Nevertheless, the fact that
Ser392 is phosphorylated in response to oncogene activation
and modulates p53 activity and stability corroborates the
concept that Twist1 participates to sarcomagenesis at least in
part by interfering with Ser392-mediated p53 activation.
How may Twist box:p53CTD interaction affect p53 response?
Recently, Prives’s group has demonstrated that, besides the
canonical N terminus, p53 engages also the CTD region to
bind MDM2, and this interaction is hampered by p53CTD
posttranslational modifications (Poyurovsky et al., 2010).
Although the authors addressed the effect of acetylation on
p53CTD:MDM2 complex formation, they argued that other
p53CTD modifications are likely to impinge on this interaction.
By using Ser392 mutants, we collected data suggesting that
Ser392 phosphorylation reduces p53 affinity to MDM2. Thus,
by hindering Ser392 phosphorylation, Twist1 might favor
p53CTD:MDM2 complex formation and hence p53 degradation.
Yet we found that Ser392 status influences also the extent of
phosphorylation at Ser15 that inhibits the interaction between
N terminus p53 and MDM2. Then, by acting on Ser392, Twist1
might in turn impinge on Ser15, thus facilitating also the canon-
ical route of MDM2-mediated degradation of p53.
Finally, in agreement with recent observations (Kogan-Sakin
et al., 2011; Lee and Bar-Sagi, 2010), we found that oncogene-
challenged human and mouse fibroblasts display increased
levels of Twist1. This suggests a scenario where oncogenic
transformation results in the induction of Twist1. In turn, Twist1
promotes the bypass of oncogene-induced p53 safeguard
responses by both inhibiting the ARF/p53 signaling and by
directly interacting with p53 and facilitating its degradation
(Figure 6H).
In conclusion, this study sheds light on the mechanisms of
Twist1-mediated inactivation of p53 and adds another important
piece of information on the role of p53CTD in the regulation of
p53 tumor-suppressive activity. Although focused on sarcomas,
our study proposes a model that might also apply to other tumor
histotypes and provides the proof of principle that targeting




Primary sarcoma samples and corresponding normal tissues were retrieved
from the Treviso General Hospital and the San Raffaele Institute tissue banks,
where they were analyzed with patients’ consent. Specimens were deidenti-
fied before analysis, and the study was approved by the IRB of CRO, Treviso
General Hospital, and San Raffaele Institute. No patient had received radio- or
chemotherapy prior to surgery. Immunohistochemistry was performed on
5-mm sections with the following antibodies: Twist1 (Twist2C1a, Santa Cruz),
Twist 2 (ab6603, Abcam), p53 (DO-7, Labvision), and MDM2 (1F2, Oncogene
Science). FISH was performed following standard protocols on 19 cases for
which frozen material was available.cer Cell 22, 404–415, September 11, 2012 ª2012 Elsevier Inc. 413
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A Twist box Code of p53 InactivationTP53 Mutation Analysis
Mutation analysis of TP53 was performed by PCR direct-sequencing on
genomic DNA extracted from paraffin-embedded tissue sections, as previ-
ously described (Dei Tos et al., 1997).
Cells, Constructs, and Protein Expression Analyses
Transfections, retroviral infections, and reporter assays were performed as
previously described (Demontis et al., 2006). Acute silencing of Twist1 was
achieved with ON-TARGETplus SMART pool siRNAs (Dharmacon), according
to the manufacturer’s instructions. Stable silencing of Twist1 was achieved by
retroviral infection of previously published Twist1-specific shRNAs (Ansieau
et al., 2008; Yang et al., 2004). shGFP and shLuciferase (shLuc) were used
as negative controls. Protein lysates were separated by SDS-PAGE and
were transferred onto nitrocellulose membrane (Protran, Whatman). Expres-
sion analyses were performed with Odyssey Infrared (Li-Cor Biosciences)
and Chemidoc (BioRad) Imaging systems, using the antibodies indicated in
Supplemental Experimental Procedures. Immunofluorescence and SA-b-gal
staining were performed as previously described (Di Micco et al., 2006; Seger
et al., 2002). GST pull-downs and in vitro CK2 assay were performed as
described in Supplemental Experimental Procedures.
Apoptosis, BrdU Incorporation, and FACS Analyses
Cell viability was assessed by Trypan blue and Viacount assay (Guava PCA)
and was calculated as mean percentage of cells that survived the apoptotic
stress (1003 viable treated cells/untreated cells). Experiments were done in
triplicate on at least two different retroviral infections. Caspase 3/7 activation
and BrdU incorporation were determined with the Apo-ONE Caspase-3/7
and the BrdU Kits (Promega). FACS analyses were done with the Cytomics
FC 500 (Beckman Coulter).
In Vivo Tumorigenicity Assay
Experiments on animals were performed in accordance with national regula-
tions and approved by the CRO animal ethics committee. RE-BJ cells (5 3
106) stably expressing MDM2, dnp53, shp53, or Twist were subcutaneously
injected into each flank of six-week-old athymic nude mice (Hsd:Athymic
nude-nu, Harlan) as previously described (Di Micco et al., 2006; Seger et al.,
2002) For pRetroSuper-shLuc and pRetroSuper-shTwist HT-1080, 1 3 106
cells were used. Tumor size was monitored weekly. Mice were sacrificed at
week 5. Tumor volume was calculated as 2r3.
Protein Modeling and Docking Simulations
Three-dimensional structure models of Twist1 and p53 were built using the
web server SAM-T08 (Karplus, 2009) and further minimized by simulated an-
nealing using the program CNS (Bru¨nger et al., 1998). Docking calculations
were carried out by the web server ClusPro 2.0 (Comeau et al., 2007).
Statistical Analysis
Data shown are means ± SD of at least three independent experiments.
Comparisons of proportions were performed using two-tailed Fisher’s exact
test.
SUPPLEMENTAL INFORMATION
Supplemental Information includes five figures, four tables, and Supple-
mental Experimental Procedures and can be found with this article online
at http://dx.doi.org/10.1016/j.ccr.2012.08.003.
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